These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11773305)

  • 1. Side effects, quality-of-life issues, and trade-offs: the patient perspective.
    Langer AS
    J Natl Cancer Inst Monogr; 2001; (30):125-9. PubMed ID: 11773305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The psychosocial experiences of women with breast cancer across the lifespan: a systematic review protocol.
    Campbell-Enns H; Woodgate R
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):112-21. PubMed ID: 26447012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?
    Simes RJ; Coates AS
    J Natl Cancer Inst Monogr; 2001; (30):146-52. PubMed ID: 11773309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).
    Gelber RD; Goldhirsch A; Hürny C; Bernhard J; Simes RJ
    J Natl Cancer Inst Monogr; 1992; (11):127-35. PubMed ID: 1385719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?
    Alarid-Escudero F; Blaes AH; Kuntz KM
    Breast J; 2017 Jul; 23(4):401-409. PubMed ID: 28117517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assisting with Decision-Making: How Standardized Information Impacts Breast Cancer Patient Decisions Regarding Fertility Trade-Offs and Chemotherapy.
    Srikanthan A; Amir E; Gupta A; Baxter N; Kennedy ED
    J Adolesc Young Adult Oncol; 2019 Dec; 8(6):660-667. PubMed ID: 31241397
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer.
    Beaver K; Williamson S; Briggs J
    Eur J Oncol Nurs; 2016 Feb; 20():77-86. PubMed ID: 26078034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Institutes of Health Consensus Development Conference Statement: Breast Cancer Screening for Women Ages 40-49, January 21-23, 1997. National Institutes of Health Consensus Development Panel.
    J Natl Cancer Inst; 1997 Jul; 89(14):1015-26. PubMed ID: 9230883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer in the elderly.
    Crivellari D; Aapro M; Leonard R; von Minckwitz G; Brain E; Goldhirsch A; Veronesi A; Muss H
    J Clin Oncol; 2007 May; 25(14):1882-90. PubMed ID: 17488987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors.
    Knobf MT
    Oncologist; 2006 Feb; 11(2):96-110. PubMed ID: 16476831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-using chemotherapy in the adjuvant setting.
    Curigliano G; Criscitiello C; Esposito A; Pruneri G
    Breast; 2017 Feb; 31():303-308. PubMed ID: 27866835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information.
    Peele PB; Siminoff LA; Xu Y; Ravdin PM
    Med Decis Making; 2005; 25(3):301-7. PubMed ID: 15951457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
    Marshall DA; Deal K; Bombard Y; Leighl N; MacDonald KV; Trudeau M
    BMJ Open; 2016 Jun; 6(6):e010981. PubMed ID: 27256091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians.
    Loprinzi CL; Ravdin PM
    J Natl Compr Canc Netw; 2003 Apr; 1(2):189-96. PubMed ID: 19768877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock.
    Goodwin PJ; Black JT; Bordeleau LJ; Ganz PA
    J Natl Cancer Inst; 2003 Feb; 95(4):263-81. PubMed ID: 12591983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.